



Press release |

## Willis Knighton Cancer Center reports 9 months of operations on Proteus<sup>®</sup>ONE: the first and only compact IMPT solution

**Willis Knighton confirms excellent performance of IBA's Proteus<sup>®</sup>ONE solution with high uptime reliability, fastest ramp up and true ease of use**

**Anaheim, California, 12 July 2015** - IBA (Ion Beam Applications S.A., EURONEXT), the world's leading provider of proton therapy solutions for the treatment of cancer, today announces that Willis-Knighton Cancer Center teams and IBA have reached unprecedented levels of quality care, ease of use and speed of treatment with IBA's compact Proton Therapy system, the Proteus<sup>®</sup>ONE.

After a record setting 11 month installation with patient treatment on September 9<sup>th</sup> 2014, the Willis-Knighton team continues to set new records by having the first compact proton therapy system in the world to treat clinically with Pencil Beam Scanning (PBS). In addition to treating more common indications such as the brain and prostate, PBS has accelerated their ramp speed by enabling new applications such as breast, head & neck, esophageal lung, spine cancer, pediatric malignancies and various pelvis indications.

IBA's Proteus<sup>®</sup>ONE system offers advantages over more limited double scattering treatment approaches and remains the only compact gantry intensity modulated proton therapy solution available in the radiation oncology community with innovations based on decades of proton therapy experience.

**Sofie Gillis PhD., Product Development Manager at IBA, commented:** "With superior workflow capabilities and an uptime above 98%, the Willis Knighton team has been able to bring the highest standard of care to their patients. We are excited to work with them to uncover even more clinical possibilities offered by Proteus<sup>®</sup>ONE."

By working together with IBA, the Willis Knighton team is currently averaging 15 minutes per patient for most indications, even with multiple fields, resulting in a daily volume of 20 patients per 8 hour day. They expect that volume to increase based upon the even faster treatment times and expanded applications that Advanced Image Guidance with Cone beam CT (CBCT) will bring them. IBA's Cone Beam CT is the only volumetric imaging solution to have obtained Marketing Authorization by the FDA and is in clinical use daily. The addition of CBCT to their Proteus<sup>®</sup>One system will bring another "1<sup>st</sup>" to Willis Knighton, since they will have the only compact PT system using CBCT for patient treatment.

**Lane R. Rosen, MD, Director of Radiation Oncology at the Willis-Knighton Cancer Center, added:** "The Proteus<sup>®</sup>ONE has exceeded all of our expectations. We are very excited to have Intensity Modulated Proton Therapy and Cone Beam CT imaging available for our patients. Both Willis-Knighton and IBA teams have been partnering at each step to ensure a smooth transition from installation to first treatment and beyond during the ramp-up of operations. We have met or exceeded all of our expectations with this collaboration and are looking forward to even more treatment options for our patients in the future"



## Press release |

**Beth Klein, President of IBA PT North America** noted; “The ProteusOne is the only compact system in the market today that incorporates both the most advanced pencil beam scanning and Cone Beam CT, setting a new standard in the Compact Proton Therapy market. To date, IBA has 10 Proteus<sup>®</sup>ONE systems installed or in process, which is an excellent demonstration of the trust that the radiation therapy community has in IBA’s innovation, experience and leading solutions designed to make this powerful technology accessible to every patient that could benefit from it.

\*\*\*ENDS\*\*\*

**Proton therapy** is considered the most advanced targeted cancer radiotherapy due to its superior dose distribution and fewer side effects. Over half of the proton facilities worldwide are equipped with IBA systems including 18 operational proton therapy centers with an additional 19 centers currently under development.

**Proteus<sup>®</sup>ONE** is the world’s first compact intensity modulated proton therapy (IMPT) solution from IBA. Proteus<sup>®</sup>ONE is more affordable, has a faster ramp up time and is easier to operate than traditional proton facilities. It benefits from the latest technologies developed over IBA’s decades of experience and benefits from the latest scanning proton technologies and on-board image guidance. Proteus<sup>®</sup>ONE is the brand name of a new configuration of the Proteus<sup>®</sup>235

**IBA** (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The Company is the worldwide technology leader in the field of proton therapy, the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full scale proton therapy centers as well as compact, single room systems. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry.

Headquartered in Belgium and employing about 1100 people worldwide, IBA has installed systems across the world, from Europe and the US and to the emerging markets. IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: [www.iba-worldwide.com](http://www.iba-worldwide.com)

**The Willis-Knighton Cancer Center**, Louisiana’s premier cancer treatment facility, based at one of the United States largest community hospitals, has been a national and international leader in advanced radiation technologies and serves as a tertiary referral center for the surrounding region.



## Press release |

For further information please contact:

### IBA

**Olivier de Sadeleer**  
Marketing Manager Proton Therapy  
+32 10 475 890  
[communication@iba-group.com](mailto:communication@iba-group.com)

**Thomas Ralet**  
Vice-President Corporate Communication  
+32 10 475 890  
[communication@iba-group.com](mailto:communication@iba-group.com)

### Willis Knighton Cancer Center

**Marilyn Joiner**  
Director of Marketing & Public Relations  
+1 318 212-8965  
[mjoiner@wkhs.com](mailto:mjoiner@wkhs.com)